Table 3.
Changes in percent proportion of CD14+ monocytes relative to all leukocytes and CD14++CD16− classical monocytes relative to all monocytes.
| Variable | Trial | BL | IP | 1H | 2H | 5H |
|---|---|---|---|---|---|---|
| % CD14+ | PL | 11.6 ± 2.7 | 10.2 ± 3.3 | 9.7 ± 2.8 | 8.4 ± 2.0 § | 7.7 ± 1.6 § |
| SUPP | 10.5 ± 3.1 | 9.2 ± 2.5 | 9.2 ± 2.9 | 7.1 ± 1.6 § | 7.5 ± 2.1 § | |
| % CD14++CD16− | PL | 86.6 ± 4.5 | 84.5 ± 5.7 | 96.4 ± 1.3 ‡ | 94.9 ± 3.1 ‡ | 91.8 ± 2.1 ‡ |
| SUPP | 84.6 ± 6.1 | 85.1 ± 5.6 | 96.0 ± 2.0 ‡ | 95.7 ± 0.8 ‡ | 90.1 ± 4.9 ‡ |
Treatment groups: PL = Placebo; SUPP = Supplement. % CD14+ = percent monocytes relative to all leukocytes; % CD14++CD16− = percent classical monocyte relative to all monocytes; Time points: BL = Baseline; IP = Immediately-post; 30P = 30 min post; 1H = One hour post; 2H = Two hours post; 5H = Five hours post. ‡ = Significant increase relative to BL (p ≤ 0.05); § = Significant decrease relative to BL (p ≤ 0.05); Data reported as means ± SD.